These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19435866)

  • 1. Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N).
    Mehibel M; Singh S; Chinje EC; Cowen RL; Stratford IJ
    Mol Cancer Ther; 2009 May; 8(5):1261-9. PubMed ID: 19435866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation enhances the therapeutic effect of Banoxantrone in hypoxic tumour cells with elevated levels of nitric oxide synthase.
    Mehibel M; Singh S; Cowen RL; Williams KJ; Stratford IJ
    Oncol Rep; 2016 Apr; 35(4):1925-32. PubMed ID: 26782976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts.
    Williams KJ; Albertella MR; Fitzpatrick B; Loadman PM; Shnyder SD; Chinje EC; Telfer BA; Dunk CR; Harris PA; Stratford IJ
    Mol Cancer Ther; 2009 Dec; 8(12):3266-75. PubMed ID: 19996276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells.
    Hejmadi MV; McKeown SR; Friery OP; McIntyre IA; Patterson LH; Hirst DG
    Br J Cancer; 1996 Feb; 73(4):499-505. PubMed ID: 8595165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone.
    Manley E; Waxman DJ
    J Pharmacol Exp Ther; 2013 Feb; 344(2):368-77. PubMed ID: 23192656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.
    McCarthy HO; Yakkundi A; McErlane V; Hughes CM; Keilty G; Murray M; Patterson LH; Hirst DG; McKeown SR; Robson T
    Cancer Gene Ther; 2003 Jan; 10(1):40-8. PubMed ID: 12489027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study.
    Albertella MR; Loadman PM; Jones PH; Phillips RM; Rampling R; Burnet N; Alcock C; Anthoney A; Vjaters E; Dunk CR; Harris PA; Wong A; Lalani AS; Twelves CJ
    Clin Cancer Res; 2008 Feb; 14(4):1096-104. PubMed ID: 18281542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N.
    Gallagher R; Hughes CM; Murray MM; Friery OP; Patterson LH; Hirst DG; McKeown SR
    Br J Cancer; 2001 Aug; 85(4):625-9. PubMed ID: 11506506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro.
    Chinje EC; Cowen RL; Feng J; Sharma SP; Wind NS; Harris AL; Stratford IJ
    Mol Pharmacol; 2003 Jun; 63(6):1248-55. PubMed ID: 12761334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents.
    Garner AP; Paine MJ; Rodriguez-Crespo I; Chinje EC; Ortiz De Montellano P; Stratford IJ; Tew DG; Wolf CR
    Cancer Res; 1999 Apr; 59(8):1929-34. PubMed ID: 10213502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
    Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.
    De Ridder M; Van Esch G; Engels B; Verovski V; Storme G
    Bull Cancer; 2008 Mar; 95(3):282-91. PubMed ID: 18390408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.
    Yakkundi A; McErlane V; Murray M; McCarthy HO; Ward C; Hughes CM; Patterson LH; Hirst DG; McKeown SR; Robson T
    Cancer Gene Ther; 2006 Jun; 13(6):598-605. PubMed ID: 16410820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug.
    Raleigh SM; Wanogho E; Burke MD; McKeown SR; Patterson LH
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):763-7. PubMed ID: 9845092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine.
    Friery OP; Gallagher R; Murray MM; Hughes CM; Galligan ES; McIntyre IA; Patterson LH; Hirst DG; McKeown SR
    Br J Cancer; 2000 Apr; 82(8):1469-73. PubMed ID: 10780528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. iNOS as a therapeutic target for treatment of human tumors.
    Fitzpatrick B; Mehibel M; Cowen RL; Stratford IJ
    Nitric Oxide; 2008 Sep; 19(2):217-24. PubMed ID: 18515106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.
    Lalani AS; Alters SE; Wong A; Albertella MR; Cleland JL; Henner WD
    Clin Cancer Res; 2007 Apr; 13(7):2216-25. PubMed ID: 17404106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional 2D Iron-Based Nanosheets for Synergistic Immunotherapy, Phototherapy, and Chemotherapy of Tumor.
    Wang X; Cheng Y; Han X; Yan J; Wu Y; Song P; Wang Y; Li X; Zhang H
    Adv Healthc Mater; 2022 Oct; 11(19):e2200776. PubMed ID: 35912918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.
    Wilson WR; Denny WA; Pullen SM; Thompson KM; Li AE; Patterson LH; Lee HH
    Br J Cancer Suppl; 1996 Jul; 27():S43-7. PubMed ID: 8763844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.
    Trédan O; Garbens AB; Lalani AS; Tannock IF
    Cancer Res; 2009 Feb; 69(3):940-7. PubMed ID: 19176397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.